Navidea Biopharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:NAVB)

$0.38 0.01 (1.33 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$0.38
Today's Range$0.37 - $0.39
52-Week Range$0.29 - $0.85
Volume135,831 shs
Average Volume352,077 shs
Market Capitalization$61.66 million
P/E Ratio-5.43
Dividend YieldN/A
Beta-0.63

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals logoNavidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNYSEAMERICAN:NAVB
CUSIP63937X10
Phone+1-614-7937500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-5.42857142857143
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.07)
Net IncomeN/A
Net Margins-688.85%
Return on Equity-38.60%
Return on Assets-25.48%

Miscellaneous

EmployeesN/A
Outstanding Shares162,260,000

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) posted its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.22 million during the quarter. Navidea Biopharmaceuticals had a negative return on equity of 38.60% and a negative net margin of 688.85%. View Navidea Biopharmaceuticals' Earnings History.

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a decline in short interest in the month of December. As of December 29th, there was short interest totalling 4,199,485 shares, a decline of 12.0% from the December 15th total of 4,773,699 shares. Based on an average trading volume of 539,880 shares, the short-interest ratio is currently 7.8 days. Approximately 2.7% of the shares of the stock are short sold.

Who are some of Navidea Biopharmaceuticals' key competitors?

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the folowing people:

  • Eric K. Rowinsky M.D., Chairman of the Board (Age 60)
  • Michael M. Goldberg M.D., President, Chief Executive Officer, Director (Age 57)
  • Jed A Latkin, Chief Financial Officer, Interim Chief Operating Officer, Chief Accounting Officer (Age 41)
  • Frederick O. Cope Ph.D., Senior Vice President - Pharmaceutical Research and Clinical Development, Chief Scientific Officer (Age 69)
  • William J. Regan, Senior Vice President - Global Regulatory Affairs and Quality Chief Compliance Officer (Age 63)
  • Mark I. Greene M.D. Ph.D., Director (Age 67)
  • Michael Rice, Director (Age 51)

How do I buy Navidea Biopharmaceuticals stock?

Shares of Navidea Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of Navidea Biopharmaceuticals stock can currently be purchased for approximately $0.38.

How big of a company is Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals has a market capitalization of $61.66 million.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.


MarketBeat Community Rating for Navidea Biopharmaceuticals (NAVB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Earnings History and Estimates Chart

Earnings by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.01)$0.22 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.02)$0.61 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.01)ViewN/AView Earnings Details
3/29/2017Q4 2016($0.02)$3.36 millionViewN/AView Earnings Details
8/4/2016Q216($0.03)($0.04)$5.24 million$5.40 millionViewN/AView Earnings Details
5/17/2016Q1($0.03)($0.02)$4.63 million$4.70 millionViewListenView Earnings Details
3/23/2016Q415($0.04)($0.02)$3.70 million$4.00 millionViewListenView Earnings Details
11/4/2015Q315($0.04)($0.05)$2.40 million$3.98 millionViewListenView Earnings Details
7/30/2015Q215($0.04)($0.06)$2.18 million$2.90 millionViewListenView Earnings Details
5/12/2015Q115($0.03)($0.05)$3.30 million$2.10 millionViewListenView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015Q414($0.05)($0.05)$2.10 million$2.20 millionViewListenView Earnings Details
11/6/2014Q314($0.06)($0.05)$1.54 million$2.30 millionViewListenView Earnings Details
8/6/2014Q214($0.07)($0.07)$1.05 million$1.05 millionViewListenView Earnings Details
5/7/2014Q114($0.10)($0.06)$0.90 million$0.75 millionViewListenView Earnings Details
3/6/2014Q413($0.08)($0.10)$0.74 million$0.54 millionViewListenView Earnings Details
11/6/2013Q313($0.08)$0.09$0.97 million$0.40 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.07)($0.09)$0.55 million$0.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.07)($0.06)$0.02 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.08)ViewN/AView Earnings Details
11/8/2012Q312$0.21($0.09)ViewN/AView Earnings Details
8/6/2012Q2 2012($0.06)($0.06)ViewN/AView Earnings Details
5/2/2012Q1 2012($0.07)($0.07)ViewN/AView Earnings Details
2/29/2012Q4 2011($0.05)($0.08)ViewN/AView Earnings Details
10/26/2011Q3 2011($0.03)($0.07)ViewN/AView Earnings Details
7/27/2011Q2 2011($0.02)($0.02)ViewN/AView Earnings Details
5/9/2011Q1 2011($0.02)($0.05)ViewN/AView Earnings Details
3/7/2011Q4 2010($0.03)($0.03)ViewN/AView Earnings Details
11/10/2010Q3 2010($0.01)($0.03)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.02)($0.02)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.01)($0.03)ViewN/AView Earnings Details
11/2/2009Q3 2009($0.31)($0.10)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.02)($0.02)ViewN/AView Earnings Details
5/6/2009Q1 2009$0.01ViewN/AView Earnings Details
3/10/2009Q4 2008($0.03)($0.02)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.02)($0.03)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.03)($0.02)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.01)($0.02)ViewN/AView Earnings Details
3/19/2008Q4 2007($0.01)($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
Institutional Ownership by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/29/2017William J ReganSVPBuy20,000$0.53$10,600.00172,977View SEC Filing  
5/30/2017Jed LatkinCFOBuy7,600$0.44$3,344.0050,159View SEC Filing  
5/22/2017Jed LatkinCFOBuy25,359$0.45$11,411.5531,359View SEC Filing  
12/1/2015Brent L LarsonCFOSell12,500$1.50$18,750.00222,237View SEC Filing  
10/1/2015Brent L LarsonCFOSell12,500$2.27$28,375.00247,237View SEC Filing  
9/1/2015Brent L LarsonCFOSell12,500$1.88$23,500.00259,737View SEC Filing  
6/1/2015Brent L LarsonCFOSell12,500$1.24$15,500.00View SEC Filing  
5/29/2015Gordon A TroupDirectorBuy10,000$1.31$13,100.00View SEC Filing  
11/14/2014Michael M GoldbergDirectorBuy100,000$1.08$108,000.00View SEC Filing  
11/10/2014Brendan A FordDirectorBuy10,000$1.03$10,300.00View SEC Filing  
5/9/2014Mark Jerome PykettCEOBuy10,000$1.34$13,400.00292,674View SEC Filing  
3/10/2014Brent LarsonCFOSell41,500$1.96$81,340.00319,184View SEC Filing  
3/10/2014Frederick CopeSVPSell15,000$1.96$29,400.0075,814View SEC Filing  
3/10/2014Mark Jerome PykettCEOSell120,000$1.96$235,200.00282,674View SEC Filing  
11/8/2013Brendan FordDirectorBuy20,000$1.45$29,000.00139,250View SEC Filing  
11/8/2013Brent LarsonCFOBuy5,000$1.39$6,950.00287,304View SEC Filing  
11/8/2013Frederick CopeSVPBuy3,500$1.43$5,005.0090,814View SEC Filing  
11/8/2013Mark Jerome PykettCEOBuy10,900$1.35$14,715.00402,674View SEC Filing  
3/15/2013Gordon A TroupDirectorBuy7,000$2.70$18,900.00View SEC Filing  
3/15/2013Mark Jerome PykettCEOBuy1,850$2.70$4,995.00View SEC Filing  
3/15/2013Thomas H TulipEVPBuy17,500$2.82$49,350.00View SEC Filing  
3/15/2013William J ReganSVPBuy5,000$2.71$13,550.00View SEC Filing  
9/14/2012Thomas H TulipEVPBuy15,000$2.70$40,500.00View SEC Filing  
9/12/2012Brendan A FordDirectorBuy5,000$2.64$13,200.00View SEC Filing  
9/11/2012Mark Jerome PykettCEOBuy4,000$2.64$10,560.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) News Headlines

Source:

SEC Filings

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.